<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7293477/table_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 3</label>
  <p>Vaccine developments by using Non-Replicating Viral Vector platform for COVID-19 according to the WHO as of April 20, 2020 (adapted from (20).</p>
 </caption>
 <thead>
  <tr>
   <th align="left" colspan="1" rowspan="1" id="0-0-.">Platform</th>
   <th align="left" colspan="1" rowspan="1" id="0-1-.">Type of candidate vaccine</th>
   <th align="left" colspan="1" rowspan="1" id="0-2-.">developer</th>
   <th align="left" colspan="1" rowspan="1" id="0-3-.">stage of clinical evaluation</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="left">Non-replicating Viral Vector</td>
   <td align="left">Ad5 Vector</td>
   <td align="left">CanSino Biological Inc. and Beijing Institute of Biotechnology</td>
   <td align="left">Phase 2 
    <br/>ChiCTR2000031781 
    <br/>Phase 1 
    <br/>ChiCTR2000030906 
   </td>
  </tr>
  <tr>
   <td/>
   <td align="left">Modified Vaccina Ankara (MVA) encoded VLP</td>
   <td align="left">GeoVax/BravoVax</td>
   <td/>
  </tr>
  <tr>
   <td/>
   <td align="left">Ad26 (alone or with MVA boost)</td>
   <td align="left">Janssen Pharmaceutical Companies</td>
   <td align="left">Pre-Clinical</td>
  </tr>
  <tr>
   <td/>
   <td align="left">ChAdOx1</td>
   <td align="left">University of Oxford</td>
   <td align="left">Phase 1/2 
    <br/>NCT04324606 
   </td>
  </tr>
  <tr>
   <td/>
   <td align="left">Ad-based Naso VAX expressing SARS2-CoV spike protein</td>
   <td align="left">Altimmune</td>
   <td align="left">Pre-clinical</td>
  </tr>
  <tr>
   <td/>
   <td align="left">Ad5 S (GREVAXâ„¢)</td>
   <td align="left">Greffex</td>
   <td align="left">Pre-clinical</td>
  </tr>
  <tr>
   <td/>
   <td align="left">Oral Vaccine platform</td>
   <td align="left">Vaxart</td>
   <td align="left">Pre-clinical</td>
  </tr>
  <tr>
   <td align="left">Replicating Viral</td>
   <td align="left">Full-length Spike or S1 
    <br/>Vector used: ChAd or (Modified Vaccina Ankara) MVA 
   </td>
   <td align="left">Zydus Cadila 
    <br/>Institut Pasteur/Themis 
    <br/>Tonix Pharma/Southern Research 
   </td>
   <td align="left">Phase I 
    <br/>(NCT03399578, 
    <br/>NCT03615911) 
   </td>
  </tr>
  <tr>
   <td align="left">Replicating Viral Vector</td>
   <td align="left">Measles Vector</td>
   <td align="left">Zydus Cadila</td>
   <td align="left">Pre-clinical</td>
  </tr>
  <tr>
   <td/>
   <td align="left">Measles Vector</td>
   <td align="left">Institute Pasteur/ Themis/ Univ. of Pittsburg Center for Vaccine Research</td>
   <td align="left">Pre-clinical</td>
  </tr>
  <tr>
   <td/>
   <td align="left">Horse pox vector expressing S protein</td>
   <td align="left">Tonix Pharma/Southern Research</td>
   <td align="left">Pre-clinical</td>
  </tr>
  <tr>
   <td/>
   <td align="left">dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen- specific CTLs</td>
   <td align="left">Shenzhen 
    <br/>Geno- Immune 
    <br/>Medical Institute 
   </td>
   <td align="left">Phase I 
    <br/>(NCT04276896) 
   </td>
  </tr>
  <tr>
   <td/>
   <td align="left">artificial antigen- presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins</td>
   <td align="left">Shenzhen 
    <br/>Geno- Immune 
    <br/>Medical Institute 
   </td>
   <td align="left">Phase I 
    <br/>(NCT04299724) 
   </td>
  </tr>
 </tbody>
</table>
